Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Intestinal Diseases 5Constipation 5Pain 3Neoplasms 2Ovarian Neoplasms 1Opioid-Induced Constipation 1Fallopian Tube Neoplasms 1Cancer Pain 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × alvimopan × Clear all
NCT01704651 2016-10-24

Accelerating Gastrointestinal Recovery

Mayo Clinic

Phase 3 Completed
146 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00135577 2015-09-02

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
67 enrolled
Other

Opioid-Induced Constipation, Constipation, Intestinal Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡